Compare UTHR & SGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | SGI |
|---|---|---|
| Founded | 1996 | 1846 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 20.2B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | SGI |
|---|---|---|
| Price | $531.38 | $75.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $531.79 | $102.00 |
| AVG Volume (30 Days) | 477.5K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 27.86 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $7.77 | $7.03 |
| Revenue Next Year | $11.11 | $5.10 |
| P/E Ratio | ★ $19.04 | $48.98 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $266.98 | $53.10 |
| 52 Week High | $548.12 | $98.56 |
| Indicator | UTHR | SGI |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 30.34 |
| Support Level | $464.92 | $69.78 |
| Resistance Level | $542.66 | $87.44 |
| Average True Range (ATR) | 14.71 | 2.47 |
| MACD | 2.68 | -0.67 |
| Stochastic Oscillator | 76.95 | 2.37 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.